Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By ...
Oregon State University researchers have developed a new nanoparticle-based photothermal therapy that uses a low-power laser ...
Scientists at McGill University and the Rosalind and Morris Goodman Cancer Institute have developed a new way to deliver ...
1d
FDA Grants Breakthrough Status To Johnson & Johnson's Cancer Drug For Advanced Head and Neck Cancer
The U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for subcutaneous Rybrevant Faspro ...
Woman's World on MSN
New pancreatic cancer drug study offers major hope for treatment
In 2026, an estimated 67,530 people will be diagnosed with pancreatic cancer, according to the American Cancer Society. But imagine a treatment that could completely eliminate pancreatic cancer tumors ...
The FDA approved Optune Pax (Novocure), a first-in-class portable device that delivers tumor-treating fields (TTFields) to ...
Spanish actor Antonio Banderas has announced that he will financially support the work of renowned bio-chemist Dr Mariano ...
The American Cancer Society’s Cancer Statistics, 2026 report highlights a historic milestone: the 5-year relative survival ...
Breakthrough personalized mRNA vaccine cuts melanoma recurrence risk by 50% when combined with Keytruda, Moderna CEO reveals promising five-year results.
SurvivorNet on MSN
Could timing give your cancer treatment a boost? New study on the best time to receive immunotherapy & chemo for non-small cell lung cancer
A new randomized clinical trial showed that receiving immunochemotherapy infusions earlier in the day may help patients with NSCLC live longer.
The FDA granted breakthrough therapy designation to Rybrevant Faspro based on data from the phase 1b/2 OrigAMI-4 study (NCT06385080).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results